Welcome to our dedicated page for INTENSITY THERAPEUTICS SEC filings (Ticker: INTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Intensity Therapeutics, Inc. (Nasdaq: INTS) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing investors with direct access to official documents and AI-assisted analysis. As a late-stage clinical biotechnology company focused on intratumoral cancer therapies, Intensity’s filings offer detailed insight into its clinical programs, financial position, capital structure, and listing status.
Key filings include periodic reports such as Form 10-K and Form 10-Q, which describe the company’s business, risk factors, and financial statements, as referenced in its proxy materials. Current reports on Form 8-K document material events, including quarterly financial results, clinical trial updates like the INVINCIBLE-4 triple-negative breast cancer study, publication of the IT-01 Phase 1/2 data, amendments to bylaws affecting quorum requirements, Nasdaq compliance communications, and securities purchase agreements for registered direct offerings.
Investors can also review the company’s definitive proxy statements on Schedule 14A, which outline matters submitted to stockholders, such as proposals to approve a reverse stock split within a specified ratio range and potential adjournments of special meetings. These documents provide context on corporate governance decisions and the company’s approach to maintaining Nasdaq Capital Market listing requirements.
On Stock Titan, AI-powered tools summarize lengthy filings, highlight key sections, and help explain complex topics such as clinical trial disclosures, capital-raising transactions, and changes to governing documents. Users can quickly locate information on Intensity’s development of INT230-6, its interactions with Nasdaq regarding stockholders’ equity and minimum bid price rules, and other regulatory events. Form 4 and related insider transaction reports, when available, can be reviewed alongside these materials to understand trading activity by directors and officers. This centralized view of INTS filings supports more efficient, document-based research into the company’s oncology-focused business and regulatory history.
Intensity Therapeutics (INTS) furnished an Item 2.02 8‑K announcing its financial results for the three and nine months ended September 30, 2025. The company released the details via a press release attached as Exhibit 99.1. The information is being furnished and shall not be deemed “filed” under the Exchange Act, nor incorporated by reference into Securities Act or Exchange Act filings except as expressly set forth by specific reference.
The 8‑K reiterates standard forward‑looking statement cautions and points readers to the company’s Form 10‑K and recent Form 10‑Qs for risk factors and additional context.
Intensity Therapeutics (NASDAQ: INTS) filed its Q3 2025 10‑Q, showing lower operating spend and continued reliance on equity financing while advancing its clinical programs. Cash and cash equivalents were
The company paused enrollment in its Phase 3 INVINCIBLE‑3 sarcoma study in March 2025 due to funding constraints and paused new enrollment in the Phase 2 INVINCIBLE‑4 TNBC study in September 2025 to revise dosing. Subsequent to quarter‑end, INTS raised
Intensity Therapeutics (INTS) launched a primary offering of 5,000,000 shares of common stock directly to an institutional investor at $0.80 per share under a Rule 424(b)(5) prospectus supplement. Gross proceeds are $4.0 million, with a 7.0% placement fee to A.G.P./Alliance Global Partners and estimated net proceeds of approximately $3.6 million after fees and expenses.
The company plans to use the funds for the advancement of clinical trials, working capital and general corporate purposes. This is a reasonable best efforts transaction; A.G.P. is acting as sole placement agent and is not purchasing the securities. Delivery is expected on or about November 3, 2025. Shares outstanding were 54,998,965 as of October 30, 2025, and are expected to be 59,998,965 after the offering. INTS last closed at $1.32 per share on October 30, 2025.
Intensity Therapeutics (INTS) entered a securities purchase agreement for a registered direct offering of 5,000,000 shares of common stock at $0.80 per share, for $4.0 million in aggregate gross proceeds. The shares are being offered off the company’s Form S-3 (File No. 333-280681), declared effective on July 11, 2024.
The transaction is expected to close on or about November 3, 2025, subject to customary closing conditions. The company engaged A.G.P./Alliance Global Partners as placement agent and agreed to pay a cash fee equal to 7.0% of gross proceeds and reimburse documented out-of-pocket expenses, including legal fees up to $50,000. The purchase agreement includes customary terms and a 30-day restriction on issuing or selling additional common stock or common stock equivalents following closing.
On October 31, 2025, the company announced pricing via a press release incorporated as an exhibit.
Intensity Therapeutics (INTS) reported voting results from its October 22, 2025 special meeting. Stockholders approved an amendment allowing a reverse stock split of common stock at a ratio between 1-for-5 and 1-for-30. The board may set the exact ratio in its sole discretion, may choose not to effect the split, and the action will not reduce the authorized number of common shares.
A quorum was present with 22,869,562 shares represented, or 46.61% of shares entitled to vote. Proposal 1 (reverse split authorization) passed with 18,333,570 For, 4,508,502 Against, and 27,490 Abstain. Proposal 2 (potential adjournment) was also approved with 18,869,741 For, 3,893,779 Against, and 106,042 Abstain.
Intensity Therapeutics reported an update on its INVINCIBLE-4 study involving its drug candidate INT230-6. The company observed a pathological complete response in the first patient evaluated in Cohort A, where patients receive two doses of INT230-6 eight days apart followed by standard immunochemotherapy. The company stated that, to date, the safety profile in Cohort A looks favorable, although some patients experienced localized skin irritation near the tumor site. Because of these local skin effects, new patient enrollment in Cohort A has been paused while the team evaluates the collected data and implements any necessary protocol adjustments before reopening enrollment.
Intensity Therapeutics (INTS) is soliciting stockholder approval for an amendment to implement a Reverse Stock Split and an adjournment proposal. As of the Record Date there were 49,055,462 shares outstanding; a quorum requires holders of at least 16,351,821 shares. The proposed Reverse Stock Split would proportionally reduce outstanding shares to between 9,811,092 and 1,635,182 shares depending on the split ratio chosen, and would increase the number of authorized but unissued shares. The board unanimously recommends a vote FOR the Amendment Proposal.
The proxy explains effects on fractional shares (cash paid in lieu), adjustments to options/warrants, no change to par value ($0.0001), and potential dilution from future issuances. The company notes capital needs and intends to seek additional financing, including an At-The-Market agreement with H.C. Wainwright. The filing summarizes U.S. federal income tax consequences, including that cash for fractions may generate capital gain or backup withholding.
Intensity Therapeutics (INTS) is asking shareholders to approve an amendment to implement a reverse stock split within a split ratio range set by the board, intended to reduce outstanding shares and potentially raise the per-share market price. The statement notes the closing price on August 27, 2025 was $0.3019 and explains the reverse split would increase the number of authorized but unissued shares, permit the board to issue additional shares without further stockholder action (subject to applicable rules), and provide cash in lieu of fractional shares.
The proxy explains voting mechanics (quorum = holders of at least one-third of voting power), vote thresholds (Amendment requires more FOR than AGAINST, with differing effects if Nasdaq listing conditions are met), tax treatment (generally non-recognition of gain or loss for U.S. Holders except for cash in lieu of fractional shares), and operational effects including adjustments to options/warrants, unchanged par value ($0.0001), and new CUSIP. The board unanimously recommends a vote FOR. The company also discloses it needs substantial additional funding and intends to raise capital via equity (including an At The Market agreement with H.C. Wainwright & Co.) or debt, warning failure to secure funding could materially affect operations.
Schedule 13G/A filed for Intensity Therapeutics, Inc. (INTS) reports that Armistice Capital, LLC and Steven Boyd collectively beneficially own 1,237,113 shares of the issuer's common stock, representing 2.56% of the class. The filing states Armistice Capital is the investment manager of the Master Fund, the direct holder of the shares, and that Armistice exercises shared voting and dispositive power over the reported shares. Mr. Boyd, as managing member, is likewise reported with shared voting and dispositive power. The Master Fund disclaims direct beneficial ownership due to its Investment Management Agreement.
Intensity Therapeutics amended its bylaws to change the quorum for stockholder meetings from a majority to at least one-third of the voting power, whether present in person, by remote communication, or represented by proxy. The Board adopted the amendment effective August 12, 2025 and filed the full text as Exhibit 3.1. Separately, Nasdaq notified the company that it was not in compliance with the $2,500,000 stockholders' equity requirement, the company raised approximately $6.6 million in July through an at-the-market offering, and its quarterly report for the period ended June 30, 2025 states it believes it meets the equity requirement. Nasdaq has determined the company currently complies but warned that failure to evidence compliance at the next periodic report could lead to delisting procedures.
FAQ
What is the current stock price of INTENSITY THERAPEUTICS (INTS)?
What is the market cap of INTENSITY THERAPEUTICS (INTS)?
